Developer docs
API playgroundTry for free, no card

Search company profiles

Aptose Biosciences

Full company profile

uuid000296y

Namestring
Aptose Biosciences
Legal namestring
Aptose Biosciences Inc.
Websiteurl
aptose.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Aptose Biosciences Inc. is a clinical-stage biopharmaceutical company incorporated under the Canada Business Corporations Act and headquartered in Toronto, Canada, with operational offices in San Diego, California. The company is publicly listed on the Toronto Stock Exchange (TSX: APS) and OTC markets (OTC: APTOF) and is currently the subject of a going-private acquisition by Hanmi Pharmaceutical Co. Ltd., announced November 19, 2025 at C$2.41 per share, with shareholder and Alberta Court approval secured in March 2026 and closing targeted for June 2026 pending Korean regulatory clearances.

Aptose develops small-molecule kinase inhibitors targeting hematologic malignancies, with its lead asset being tuspetinib (TUS), an oral myeloid kinase inhibitor (MKI) that potently inhibits SYK, FLT3 (mutated and wildtype), JAK, c-KIT(mut), and RSK2. Tuspetinib is being evaluated in the Phase 1/2 TUSCANY trial as triplet therapy with venetoclax and azacitidine (TUS+VEN+AZA) for newly diagnosed AML patients ineligible for induction chemotherapy; interim data reported an 86.2% composite complete response rate across 29 evaluable patients and 100% CRc in TP53-mutated/complex-karyotype patients at the 160 mg dose. A second asset, luxeptinib (LUX), was returned to original licensor CGI Invites Co., Ltd. in May 2026, narrowing the pipeline to tuspetinib ahead of the Hanmi closing. Aptose licensed tuspetinib from Hanmi in November 2021, and Hanmi has since become both the largest shareholder (~20% pre-acquisition) and sole material financial backer, providing over $41 million in debt facilities over 18 months.

Aptose is pre-revenue with no commercialized products and operates a cost-intensive clinical development model funded by equity issuances and Hanmi debt advances; the company reported a net loss of $25.5 million in FY2025 and $7.6 million in Q1 2026 with $4.1 million in cash at March 31, 2026. The go-to-market strategy centers on advancing tuspetinib through Phase 1/2 at 10 leading U.S. academic clinical sites, with commercialization to be pursued post-acquisition through Hanmi's resources. Customers in the traditional sense are absent; the company's primary counterparty is Hanmi Pharmaceutical, and its end-users are AML patients enrolled in clinical trials rather than paying accounts.

Short descriptiontext

Aptose Biosciences is a clinical-stage biopharmaceutical company developing tuspetinib, an oral multi-kinase inhibitor for acute myeloid leukemia. Pre-revenue and currently being acquired by Hanmi Pharmaceutical (C$2.41/share) with closing targeted for June 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hematology drug development, kinase inhibitor therapeutics, oncology clinical trials, precision oncology medicines, AML treatment pipeline
Industry1 code
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Hematology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-commercial / Clinical Stage Revenue
TypeSubscription Recurring
Description

Aptose is a clinical-stage biotechnology company with no commercialized products generating revenue. The company relies on financing activities, including equity offerings, private placements, and debt facilities from Hanmi Pharmaceutical, to fund ongoing clinical development of tuspetinib and luxeptinib.

aptose.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aptose Biosciences is a clinical-stage biopharmaceutical company developing proprietary small-molecule kinase inhibitor drug candidates for hematologic malignancies, principally acute myeloid leukemia (AML). Its lead candidate tuspetinib (TUS) is an oral multi-kinase inhibitor being evaluated in the Phase 1/2 TUSCANY trial as triplet therapy (TUS+VEN+AZA) for newly diagnosed AML patients ineligible for induction chemotherapy. A second candidate, luxeptinib (LUX), a BTK/FLT3 inhibitor for B-cell malignancies and AML/MDS, had its license returned to CGI Invites Co., Ltd. in May 2025.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Aptose Biosciences is a clinical-stage precision oncology company developing a pipeline of small molecule cancer therapeutics focused on hematologic malignancies. The core product portfolio includes: (1) Tuspetinib (TUS), an oral myeloid kinase inhibitor targeting SYK, FLT3, JAK, and c-KIT(mut), being developed for AML in the Phase 1/2 TUSCANY trial as triplet therapy with venetoclax and azacitidine, and previously studied in the APTIVATE monotherapy/combination trial; (2) Luxeptinib (LUX), a lymphoid and myeloid kinome inhibitor targeting BTK and FLT3, in Phase 1a/b trials for B-cell malignancies (CLL, NHL) and AML/MDS. Note: Aptose has returned the license rights for Luxeptinib to CGI Invites Co., Ltd.

Product and service2 records
1Tuspetinib (TUS)
CategoryDrug Candidate
Description

Tuspetinib is a potent oral inhibitor of key kinases operative in myeloid malignancies, including SYK, FLT3, JAK, c-KIT(mut), and others. It is being developed for acute myeloid leukemia (AML) treatment both as monotherapy and in combination therapy (TUS+VEN+AZA triplet).

2Luxeptinib (LUX)
CategoryDrug Candidate
Description

Luxeptinib is a potent non-covalent inhibitor of wildtype and mutant forms of BTK, as well as multiple oncogenic signaling pathways operative in CLL and other B-cell malignancies, and was also being developed as a myeloid kinome inhibitor (MKI) for AML and MDS.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthersAnnounced on2025-05-13
Description

Luxeptinib (formerly CG-806) was licensed from CGI under a 2016 agreement (updated in 2018). Aptose and CGI entered into a Termination of License Agreement in May 2025, with Aptose returning the license rights to CGI. The compound is now being returned to its original developer.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Astellas markets Xospata (gilteritinib), an FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. It is a direct competitor to Aptose's tuspetinib, which also targets FLT3 (mutated and wildtype) within its multi-kinase inhibition profile, addressing overlapping AML patient populations.

TypeDirect peer
Description

Daiichi Sankyo markets Vanflyta (quizartinib) for FLT3-mutated AML, both in frontline combination with chemotherapy and as maintenance therapy. It competes directly with Aptose's tuspetinib in FLT3-driven AML and represents a meaningful comparator in FLT3 inhibitor efficacy and safety.

TypeBroad incumbent
Description

AbbVie (with Genentech/Roche) markets venetoclax (VENCLEXTA), which is a core component of Aptose's TUS+VEN+AZA triplet. While not a direct molecular competitor, AbbVie is the dominant player in AML combination therapy and any changes to venetoclax pricing, access, or labeling would materially impact Aptose's commercial prospects.

TypeDirect peer
Description

Servier (which acquired Agios's oncology business) markets Tibsovo (ivosidenib) for IDH1-mutated AML. It is a direct competitor in the molecularly stratified AML space, and its established commercial infrastructure in AML offers a relevant comparator for go-to-market strategy.

5Bristol-Myers Squibb
TypeBroad incumbent
Description

Bristol-Myers Squibb operates a broad oncology franchise including AML therapeutics (e.g., azacitidine co-promotion and idasanutlin development). As a major incumbent, it competes for AML market share and provides relevant comparison points on commercial scale, regulatory strategy, and combination trial design.

TypeDirect peer
Description

Kura Oncology is a clinical-stage precision oncology company developing KO-539, a menin inhibitor for NPM1-mutated and KMT2A-rearranged AML. It is a closely comparable clinical-stage AML peer with similar development stage, target indication overlap, and pipeline concentration risk profile.

TypeDirect peer
Description

GlycoMimetics is a clinical-stage hematology-focused company developing uproleselan and other E-selectin-based therapeutics for AML. It is a direct peer in clinical-stage AML drug development with comparable size, public-market status, and indication focus.

TypeEmerging player
Description

Aprea Therapeutics is a clinical-stage oncology company developing eprenetapopt (APR-246) for TP53-mutated malignancies, including AML/MDS. It is a relevant peer given the shared focus on TP53-mutated patient populations — a key differentiation area for Aptose's tuspetinib.

TypeEmerging player
Description

Relay Therapeutics is a clinical-stage precision oncology company leveraging computational approaches to develop targeted therapies including RLY-4008 and PI3Kα inhibitors. It is a comparable precision-oncology peer with similar clinical-stage profile and investor base dynamics.

TypeOthers
Description

Schrödinger is a computational drug discovery platform company that develops small molecule therapeutics internally and partners with pharma. It is thematically related as a platform-enabled small molecule drug developer, and its internal pipeline includes oncology programs, providing a relevant comparator for capital-efficient drug discovery models.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aptose Biosciences

Hematology Pharmaceuticalsaptose.com

Aptose Biosciences is a clinical-stage biopharmaceutical company developing tuspetinib, an oral multi-kinase inhibitor for acute myeloid leukemia. Pre-revenue and currently being acquired by Hanmi Pharmaceutical (C$2.41/share) with closing targeted for June 2026.

What Aptose Biosciences does

Aptose Biosciences Inc. is a clinical-stage biopharmaceutical company incorporated under the Canada Business Corporations Act and headquartered in Toronto, Canada, with operational offices in San Diego, California. The company is publicly listed on the Toronto Stock Exchange (TSX: APS) and OTC markets (OTC: APTOF) and is currently the subject of a going-private acquisition by Hanmi Pharmaceutical Co. Ltd., announced November 19, 2025 at C$2.41 per share, with shareholder and Alberta Court approval secured in March 2026 and closing targeted for June 2026 pending Korean regulatory clearances.

Aptose develops small-molecule kinase inhibitors targeting hematologic malignancies, with its lead asset being tuspetinib (TUS), an oral myeloid kinase inhibitor (MKI) that potently inhibits SYK, FLT3 (mutated and wildtype), JAK, c-KIT(mut), and RSK2. Tuspetinib is being evaluated in the Phase 1/2 TUSCANY trial as triplet therapy with venetoclax and azacitidine (TUS+VEN+AZA) for newly diagnosed AML patients ineligible for induction chemotherapy; interim data reported an 86.2% composite complete response rate across 29 evaluable patients and 100% CRc in TP53-mutated/complex-karyotype patients at the 160 mg dose. A second asset, luxeptinib (LUX), was returned to original licensor CGI Invites Co., Ltd. in May 2026, narrowing the pipeline to tuspetinib ahead of the Hanmi closing. Aptose licensed tuspetinib from Hanmi in November 2021, and Hanmi has since become both the largest shareholder (~20% pre-acquisition) and sole material financial backer, providing over $41 million in debt facilities over 18 months.

Aptose is pre-revenue with no commercialized products and operates a cost-intensive clinical development model funded by equity issuances and Hanmi debt advances; the company reported a net loss of $25.5 million in FY2025 and $7.6 million in Q1 2026 with $4.1 million in cash at March 31, 2026. The go-to-market strategy centers on advancing tuspetinib through Phase 1/2 at 10 leading U.S. academic clinical sites, with commercialization to be pursued post-acquisition through Hanmi's resources. Customers in the traditional sense are absent; the company's primary counterparty is Hanmi Pharmaceutical, and its end-users are AML patients enrolled in clinical trials rather than paying accounts.

Aptose Biosciences firmographics

Firmographics
Name
Aptose Biosciences
Legal name
Aptose Biosciences Inc.
Website
https://aptose.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Aptose Biosciences is a clinical-stage biopharmaceutical company developing tuspetinib, an oral multi-kinase inhibitor for acute myeloid leukemia. Pre-revenue and currently being acquired by Hanmi Pharmaceutical (C$2.41/share) with closing targeted for June 2026.
Ownership category
akta.pro rank

Aptose Biosciences industry classification

Industry
Product category
Hematology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)

Keywords

  • Hematology drug development
  • Kinase inhibitor therapeutics
  • Oncology clinical trials
  • Precision oncology medicines
  • AML treatment pipeline

Where Aptose Biosciences is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Aptose Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pre-commercial / Clinical Stage Revenue: Aptose is a clinical-stage biotechnology company with no commercialized products generating revenue. The company relies on financing activities, including equity offerings, private placements, and debt facilities from Hanmi Pharmaceutical, to fund ongoing clinical development of tuspetinib and luxeptinib.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Aptose Biosciences product offering

Product offering

Core offering

Aptose Biosciences is a clinical-stage biopharmaceutical company developing proprietary small-molecule kinase inhibitor drug candidates for hematologic malignancies, principally acute myeloid leukemia (AML). Its lead candidate tuspetinib (TUS) is an oral multi-kinase inhibitor being evaluated in the Phase 1/2 TUSCANY trial as triplet therapy (TUS+VEN+AZA) for newly diagnosed AML patients ineligible for induction chemotherapy. A second candidate, luxeptinib (LUX), a BTK/FLT3 inhibitor for B-cell malignancies and AML/MDS, had its license returned to CGI Invites Co., Ltd. in May 2025.

Product overview

Aptose Biosciences is a clinical-stage precision oncology company developing a pipeline of small molecule cancer therapeutics focused on hematologic malignancies. The core product portfolio includes: (1) Tuspetinib (TUS), an oral myeloid kinase inhibitor targeting SYK, FLT3, JAK, and c-KIT(mut), being developed for AML in the Phase 1/2 TUSCANY trial as triplet therapy with venetoclax and azacitidine, and previously studied in the APTIVATE monotherapy/combination trial; (2) Luxeptinib (LUX), a lymphoid and myeloid kinome inhibitor targeting BTK and FLT3, in Phase 1a/b trials for B-cell malignancies (CLL, NHL) and AML/MDS. Note: Aptose has returned the license rights for Luxeptinib to CGI Invites Co., Ltd.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tuspetinib (TUS) Tuspetinib is a potent oral inhibitor of key kinases operative in myeloid malignancies, including SYK, FLT3, JAK, c-KIT(mut), and others. It is being developed for acute myeloid leukemia (AML) treatment both as monotherapy and in combination therapy (TUS+VEN+AZA triplet).
  • Luxeptinib (LUX) Luxeptinib is a potent non-covalent inhibitor of wildtype and mutant forms of BTK, as well as multiple oncogenic signaling pathways operative in CLL and other B-cell malignancies, and was also being developed as a myeloid kinome inhibitor (MKI) for AML and MDS.

Companies that use Aptose Biosciences

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Aptose Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aptose Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CGI Invites Co., Ltd. (CGI)minorOthers · 13 May 2025Luxeptinib (formerly CG-806) was licensed from CGI under a 2016 agreement (updated in 2018). Aptose and CGI entered into a Termination of License Agreement in May 2025, with Aptose returning the license rights to CGI. The compound is now being returned to its original developer.

Scale indicators6 records

Recent moves8 records

Expansion highlights4 records

Aptose Biosciences competitors and assessment

Company assessment

Direct peers

  • Astellas Pharma: Astellas markets Xospata (gilteritinib), an FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. It is a direct competitor to Aptose's tuspetinib, which also targets FLT3 (mutated and wildtype) within its multi-kinase inhibition profile, addressing overlapping AML patient populations.
  • Daiichi Sankyo: Daiichi Sankyo markets Vanflyta (quizartinib) for FLT3-mutated AML, both in frontline combination with chemotherapy and as maintenance therapy. It competes directly with Aptose's tuspetinib in FLT3-driven AML and represents a meaningful comparator in FLT3 inhibitor efficacy and safety.
  • Servier: Servier (which acquired Agios's oncology business) markets Tibsovo (ivosidenib) for IDH1-mutated AML. It is a direct competitor in the molecularly stratified AML space, and its established commercial infrastructure in AML offers a relevant comparator for go-to-market strategy.
  • Kura Oncology: Kura Oncology is a clinical-stage precision oncology company developing KO-539, a menin inhibitor for NPM1-mutated and KMT2A-rearranged AML. It is a closely comparable clinical-stage AML peer with similar development stage, target indication overlap, and pipeline concentration risk profile.
  • GlycoMimetics: GlycoMimetics is a clinical-stage hematology-focused company developing uproleselan and other E-selectin-based therapeutics for AML. It is a direct peer in clinical-stage AML drug development with comparable size, public-market status, and indication focus.

Broad incumbents

  • AbbVie: AbbVie (with Genentech/Roche) markets venetoclax (VENCLEXTA), which is a core component of Aptose's TUS+VEN+AZA triplet. While not a direct molecular competitor, AbbVie is the dominant player in AML combination therapy and any changes to venetoclax pricing, access, or labeling would materially impact Aptose's commercial prospects.
  • Bristol-Myers Squibb: Bristol-Myers Squibb operates a broad oncology franchise including AML therapeutics (e.g., azacitidine co-promotion and idasanutlin development). As a major incumbent, it competes for AML market share and provides relevant comparison points on commercial scale, regulatory strategy, and combination trial design.

Emerging players

  • Aprea Therapeutics: Aprea Therapeutics is a clinical-stage oncology company developing eprenetapopt (APR-246) for TP53-mutated malignancies, including AML/MDS. It is a relevant peer given the shared focus on TP53-mutated patient populations — a key differentiation area for Aptose's tuspetinib.
  • Relay Therapeutics: Relay Therapeutics is a clinical-stage precision oncology company leveraging computational approaches to develop targeted therapies including RLY-4008 and PI3Kα inhibitors. It is a comparable precision-oncology peer with similar clinical-stage profile and investor base dynamics.

Others

  • Schrödinger: Schrödinger is a computational drug discovery platform company that develops small molecule therapeutics internally and partners with pharma. It is thematically related as a platform-enabled small molecule drug developer, and its internal pipeline includes oncology programs, providing a relevant comparator for capital-efficient drug discovery models.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Aptose Biosciences social profiles

Digital presence

Aptose Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aptose Biosciences leadership team

Management profile

Number of profiles

Profiles3 records

Aptose Biosciences funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aptose Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptose Biosciences

What does Aptose Biosciences do?

Aptose Biosciences is a clinical-stage biopharmaceutical company developing proprietary small-molecule kinase inhibitor drug candidates for hematologic malignancies, principally acute myeloid leukemia (AML). Its lead candidate tuspetinib (TUS) is an oral multi-kinase inhibitor being evaluated in the Phase 1/2 TUSCANY trial as triplet therapy (TUS+VEN+AZA) for newly diagnosed AML patients ineligible for induction chemotherapy. A second candidate, luxeptinib (LUX), a BTK/FLT3 inhibitor for B-cell malignancies and AML/MDS, had its license returned to CGI Invites Co., Ltd. in May 2025.

Is Aptose Biosciences a public or private company?

Aptose Biosciences is a public company. It is classified as public and is currently operating.

When was Aptose Biosciences founded?

Aptose Biosciences was founded in 2014. It employs 11 to 50 people.

Where is Aptose Biosciences based?

Aptose Biosciences is headquartered in San Diego, United States, in the North America region.

How does Aptose Biosciences make money?

One revenue line is on record: pre-commercial / Clinical Stage Revenue.

Who are Aptose Biosciences's main competitors?

Direct peers on record are Astellas Pharma, Daiichi Sankyo, Servier, Kura Oncology and GlycoMimetics. Broad incumbents are AbbVie and Bristol-Myers Squibb. Emerging players are Aprea Therapeutics and Relay Therapeutics. Schrödinger is listed as an others.

Does Aptose Biosciences have an API?

No public API is recorded for Aptose Biosciences.

What industry is Aptose Biosciences in?

Aptose Biosciences's product category is Hematology Pharmaceuticals. Its primary akta.pro industry code is HLAIABAG, Generic APIs & Intermediates (Active Ingredients). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Globe and MailHanmi Completes Acquisition, Taking Aptose Biosciences PrivateHanmi Pharmaceutical's subsidiary acquired Aptose Biosciences' remaining shares on June 30, 2026, paying C$2.41 per share, a 28% premium to the prior VWAP. The deal, approved by shareholders and courts, will delist Aptose from the TSX around July 3, 2026, and end its public reporting obligations in Canada and the U.S.BioSpaceAptose Biosciences Announces Completion of Acquisition by Hanmi PharmaceuticalAptose Biosciences completed its acquisition by Hanmi Pharmaceutical, with Hanmi paying C$2.41 per share, a 28% premium over the 30-day VWAP. The deal was approved by shareholders and court, and the shares are expected to be delisted from the TSX on July 3, 2026.FinancialContent Business PageAptose Biosciences Announces Completion of Acquisition by Hanmi PharmaceuticalHanmi Pharmaceutical Co. Ltd., through its subsidiary HS North America Ltd., completed the acquisition of Aptose Biosciences Inc. on June 30, 2026, acquiring all outstanding common shares not already owned for C$2.41 per share, representing a 28% premium over Aptose's 30-day VWAP of C$1.88 on the Toronto Stock Exchange. The arrangement received shareholder approval on March 31, 2026, and necessary regulatory approvals from Korea. As a result, Aptose's common shares are expected to be delisted from the TSX around July 3, 2026, and the company will cease to be a reporting issuer under Canadian and U.S. securities laws.GlobeNewswireAptose Biosciences Announces Completion of Acquisition by Hanmi PharmaceuticalAptose Biosciences Inc., a clinical-stage precision oncology company developing tuspetinib-based therapy for acute myeloid leukemia, has completed its acquisition by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd. Under the arrangement terms, Aptose shareholders received C$2.41 per share in cash, representing a 28% premium over the company's 30-day volume-weighted average price, with the transaction receiving shareholder and regulatory approvals in Korea. The company's shares are expected to be delisted from the Toronto Stock Exchange on or about July 3, 2026.Stock TitanAptose Biosciences closes Hanmi acquisitionAptose Biosciences announced the closing of its acquisition by Hanmi Pharmaceutical's subsidiary, HS North America Ltd., with Aptose shareholders receiving C$2.41 per share in cash, representing a 28% premium over the company's 30-day volume-weighted average price. The arrangement received shareholder and court approvals on March 31, 2026, along with necessary regulatory approvals in Korea. Aptose's common shares are expected to be delisted from the Toronto Stock Exchange on or about July 3, 2026, and the company has submitted applications to cease being a reporting issuer under applicable Canadian and U.S. securities laws.AInvestThe 21-Cent Edge: Why APOG's Risky Label Is Missing the Arbitrage SetupHanmi Pharmaceutical's C$2.41 per share acquisition of Aptose Biosciences received shareholder approval on March 31, 2026, with final court approval granted, though the deal still requires U.S. regulatory clearance. Shares currently trade around C$2.20 versus the C$2.41 deal price, creating an 8.7% arbitrage spread that the article argues represents a favorable risk/reward setup given Hanmi's sunk costs in the drug program and positive TUSCANY trial data. The article advises investors not to be deterred by Aptose's poor fundamentals (Q1 2026 net loss of $7.6M, $34.7M shareholders' deficit, and Nasdaq delisting) since the deal creates a defined floor if it closes.Investing.comAptose reports 86% response rate in AML triplet therapy trial By Investing.comAptose Biosciences presented Phase 1/2 TUSCANY trial data at the European Hematology Association Congress, showing an 86.2% composite complete response rate among 29 evaluable AML patients treated with tuspetinib combined with venetoclax and azacitidine. The trial enrolled 32 patients ineligible for induction chemotherapy across four dose levels, with a minimal residual disease-negative rate of 62.5% overall and 86.2% among those achieving complete remission. No treatment-related deaths or adverse events were reported, and 19 subjects remain on treatment with six having proceeded to stem cell transplantation.Financial PostAptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral PresentationAptose Biosciences presented clinical data from the TUSCANY Phase 1/2 trial of tuspetinib (TUS) triplet therapy (TUS+VEN+AZA) for newly diagnosed AML at the 2026 EHA Congress, reporting an 86.2% complete remission (CRc) rate among 29 response-evaluable patients and a 62.5% MRD-negative rate overall. The 160 mg dose cohort showed a 76.9% CRc rate with 100% composite complete remission in TP53-mutation patients with complex karyotype, while 19 subjects remain on treatment including 6 who proceeded to stem cell transplantation, with no treatment-related deaths or significant adverse events reported.Stock TitanAptose reports 86.2% CRc in TUSCANY AML tripletAptose Biosciences announced positive Phase 1/2 TUSCANY trial data at the 2026 European Hematology Association Congress in Stockholm, Sweden, showing an 86.2% composite complete response rate in 29 evaluable newly diagnosed AML patients treated with tuspetinib combined with venetoclax and azacitidine. The triplet therapy demonstrated particular efficacy in historically difficult-to-treat populations, including a 100% CRc rate in TP53-mutated patients at the 160 mg dose level, with an 86.4% MRD-negativity rate among responders. The therapy is being developed as a mutation-agnostic frontline treatment for AML patients ineligible for induction chemotherapy, with 19 subjects remaining on treatment including 6 who proceeded to stem cell transplantation.GlobeNewswireAptose Presents Safety, Response, and MRD Clinical DataAptose Biosciences announced clinical data from the TUSCANY Phase 1/2 trial showing an 86.2% composite complete response rate in newly diagnosed AML patients treated with the TUS+VEN+AZA triplet therapy across 32 patients at four dose levels. The 160mg dose cohort demonstrated a 100% complete remission rate in patients with TP53 mutations and complex karyotypes, historically difficult to treat, with 19 patients remaining on treatment including 6 who proceeded to stem cell transplantation. The data was presented at the European Hematology Association Congress 2026 in Stockholm, Sweden.